1380427-97-3

Basic information

• Product Name: C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S
• Synonyms: C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S
• CAS NO: 1380427-97-3
• Molecular Weight: 630.568
• Mol File: 1380427-97-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S(1380427-97-3)
• EPA Substance Registry System: C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S(1380427-97-3)

Safety Data

• Hazardous Substances Data: 1380427-97-3(Hazardous Substances Data)

Upstream product

• 224776-34-5 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone 
• 224776-32-3 methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate 
• 1295583-21-9 methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate 
• 689251-97-6 (E)-3-(1-methyl-1H-pyrazol-4-yl)acrylic acid 
• 1380427-95-1 2-((3-methoxy-4-(3-(trifluoromethyl)phenoxy)benzyl)thio)-5-((1-methyl-1H-pyrazol-4-yl)methyl)pyrimidin-4(1H)-one 
• 76-05-1 trifluoroacetic acid 
• 74-88-4 methyl iodide 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 

Relevant articles and documents

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).